JPWO2020007938A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020007938A5 JPWO2020007938A5 JP2020573396A JP2020573396A JPWO2020007938A5 JP WO2020007938 A5 JPWO2020007938 A5 JP WO2020007938A5 JP 2020573396 A JP2020573396 A JP 2020573396A JP 2020573396 A JP2020573396 A JP 2020573396A JP WO2020007938 A5 JPWO2020007938 A5 JP WO2020007938A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- ring
- acceptable salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 10
- 201000003883 Cystic fibrosis Diseases 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18181475 | 2018-07-03 | ||
| EP18181475.7 | 2018-07-03 | ||
| PCT/EP2019/067899 WO2020007938A1 (en) | 2018-07-03 | 2019-07-03 | PqsR INVERSE AGONISTS |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021529203A JP2021529203A (ja) | 2021-10-28 |
| JP2021529203A5 JP2021529203A5 (https=) | 2022-07-04 |
| JPWO2020007938A5 true JPWO2020007938A5 (https=) | 2022-07-04 |
| JP7399898B2 JP7399898B2 (ja) | 2023-12-18 |
Family
ID=62846069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573396A Active JP7399898B2 (ja) | 2018-07-03 | 2019-07-03 | ＰｑｓＲインバースアゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11883387B2 (https=) |
| EP (1) | EP3818045A1 (https=) |
| JP (1) | JP7399898B2 (https=) |
| AU (1) | AU2019297409B2 (https=) |
| CA (1) | CA3103351A1 (https=) |
| WO (1) | WO2020007938A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3164264A1 (en) * | 2020-01-02 | 2021-07-08 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | Novel pqsr inverse agonists |
| US12528783B2 (en) | 2020-01-02 | 2026-01-20 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | PqsR inverse agonists |
| WO2024186827A2 (en) * | 2023-03-06 | 2024-09-12 | The Regents Of The University Of California | Novel host-directed therapeutic agent for the treatment of infectious diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8877940B2 (en) | 2011-02-22 | 2014-11-04 | Institut National De La Recherche Scientifique | Antibiotic tolerance inhibitors |
| US9643933B2 (en) | 2013-04-23 | 2017-05-09 | The General Hospital Corporation | Compounds useful as antibiotic tolerance inhibitors |
| WO2016007837A1 (en) | 2014-07-11 | 2016-01-14 | Spero Therapeutics, Inc. | Carbonyl linked bicyclic heteroaryl antibiotic tolerance inhibitors |
| WO2016040764A1 (en) | 2014-09-12 | 2016-03-17 | Spero Therapeutics, Inc. | Carbonyl linked bicyclic heteroaryl n-benzimidazoles and analogs as antibiotic tolerance inhibitors |
| WO2016112088A1 (en) | 2015-01-06 | 2016-07-14 | Spero Therapeutics, Inc. | Aryloxyacetylindoles and analogs as antibiotic tolerance inhibitors |
| BR112018016329A2 (pt) | 2016-02-10 | 2018-12-18 | Janssen Pharmaceutica Nv | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b |
| CN108003151B (zh) * | 2016-10-27 | 2019-11-05 | 湖南化工研究院有限公司 | N-杂芳基甲基嘧啶胺类化合物及其制备方法与应用 |
-
2019
- 2019-07-03 US US17/257,804 patent/US11883387B2/en active Active
- 2019-07-03 EP EP19741977.3A patent/EP3818045A1/en active Pending
- 2019-07-03 JP JP2020573396A patent/JP7399898B2/ja active Active
- 2019-07-03 AU AU2019297409A patent/AU2019297409B2/en active Active
- 2019-07-03 WO PCT/EP2019/067899 patent/WO2020007938A1/en not_active Ceased
- 2019-07-03 CA CA3103351A patent/CA3103351A1/en active Pending